Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd(NYU Langone Health), Robert H. Vonderheide(University of Pennsylvania)
Cited by 467
Related Papers
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>
|Journal of Clinical Oncology|2021|238
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
|Clinical Cancer Research|2021|178
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
|The Journal of Experimental Medicine|2020|175
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder
|American Journal of Transplantation|2015|174
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
|Journal of Clinical Investigation|2019|167